

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



SINO BIOPHARMACEUTICAL LIMITED

中國生物製藥有限公司

(Incorporated in the Cayman Islands with limited liability)

Website: www.sinobiopharm.com

(Stock code: 1177)

VOLUNTARY ANNOUNCEMENT
“SITAGLIPTIN PHOSPHATE TABLET”
OBTAINED DRUG REGISTRATION CERTIFICATES

The board of directors (the “**Board**”) of Sino Biopharmaceutical Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) announces that “Sitagliptin Phosphate Tablet” (trade name: Pin Ding (品定)) (product specifications: 50mg and 100mg), a drug developed by the Group for treatment of diabetes, has been granted drug registration certificates by the National Medical Products Administration of China and is deemed to have passed the consistency evaluation of quality and efficacy of generic drugs.

Sitagliptin is the world’s first oral dipeptidyl peptidase-4 (DPP-4) inhibitor approved for use in combination with diet and exercise to improve glycaemic control in patients with type 2 diabetes. Clinical data showed that sitagliptin has basically no risk of hypoglycaemia, no dose titration and no gastrointestinal reactions, and is effective in controlling blood glucose and slowing the progression of diabetes when taken orally once daily.

Tested by over tens of millions of prescriptions worldwide, Sitagliptin Phosphate Tablet has demonstrated effective hypoglycaemic efficacy and good safety profile. It has been recommended by a number of authoritative guidelines in China and overseas, and included in China's national medical insurance. The approval of the Group's another Sitagliptin Phosphate Tablet product will provide diabetic patients in China with more choices and reduce their burden of medication.

By order of the Board
Sino Biopharmaceutical Limited
Tse, Theresa Y Y
Chairwoman

Hong Kong, 10 March 2022

As at the date of this announcement, the Board of the Company comprises nine executive directors, namely Ms. Tse, Theresa Y Y, Mr. Tse Ping, Ms. Cheng Cheung Ling, Mr. Tse, Eric S Y, Mr. Tse Hsin, Mr. Li Yi, Mr. Wang Shanchun, Mr. Tian Zhoushan and Ms. Li Mingqin and five independent non-executive directors, namely Mr. Lu Zhengfei, Mr. Li Dakui, Ms. Lu Hong, Mr. Zhang Lu Fu and Dr. Li Kwok Tung Donald.